Deutsche Bank AG Reiterates “€95.00” Price Target for Sanofi SA (SAN)
Several other equities research analysts also recently issued reports on the company. Kepler Capital Markets set a €91.00 ($100.00) price objective on Sanofi SA and gave the stock a buy rating in a research note on Thursday, July 7th. JPMorgan Chase & Co. set a €71.00 ($78.02) price objective on Sanofi SA and gave the stock a sell rating in a research note on Thursday, September 15th. Jefferies Group set a €76.00 ($83.52) price objective on Sanofi SA and gave the stock a neutral rating in a research note on Tuesday, September 13th. Berenberg Bank set a €93.00 ($102.20) price objective on Sanofi SA and gave the stock a buy rating in a research note on Thursday, September 8th. Finally, Societe Generale set a €100.00 ($109.89) price objective on Sanofi SA and gave the stock a buy rating in a research note on Monday, August 1st. One research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the stock. Sanofi SA has an average rating of Hold and an average target price of €86.18 ($94.70).
Sanofi SA (EPA:SAN) opened at 67.88 on Thursday. Sanofi SA has a 52-week low of €22.81 and a 52-week high of €68.49. The firm has a market capitalization of €87.36 billion and a price-to-earnings ratio of 21.11. The company’s 50-day moving average price is €25.93 and its 200 day moving average price is €25.76.
About Sanofi SA
Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.
Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.